0.7017

1.03% -0.0073

After Hours: .69 -0.0117 -1.67%

Galmed Pharmaceuticals Ltd (GLMD)

Overview News Price History Why GLMD Down? Discussions Forecast Stock Split

Galmed Pharmaceuticals Ltd stock is traded at $0.7017, with a volume of 498.69K. It is down -1.03% in the last 24 hours and up +11.38% over the past month. Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.

Previous Close:

$0.709

Open:

$0.7277

24h Volume:

498.69K

Relative Volume:

0.18

Market Cap:

$4.63M

Revenue:

Net Income/Loss:

$-10.31M

P/E Ratio:

-0.3011

EPS:

-2.3308

Net Cash Flow:

$-6.32M

1W Performance:

+12.73%

1M Performance:

+11.38%

6M Performance:

-51.94%

1Y Performance:

-50.23%

1-Day Range:

$0.6709

$0.735

1-Week Range:

$0.66

$1.26

52-Week Range:

$0.4111

$2.68

Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile

Name

Galmed Pharmaceuticals Ltd

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

Address

Employee

Twitter

@GalmedPharma

Next Earnings Date

2026-04-01

Latest SEC Filings

GLMD's Discussions on Twitter

Compare GLMD vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLMD Galmed Pharmaceuticals Ltd	0.7017	4.68M	0	-10.31M	-6.32M	-2.3308
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-22-20	Downgrade	B. Riley FBR	Buy → Neutral
Feb-04-20	Initiated	Craig Hallum	Buy
Jan-30-20	Resumed	Cantor Fitzgerald	Overweight
Dec-02-19	Initiated	Canaccord Genuity	Buy
Dec-12-18	Initiated	B. Riley FBR	Buy
Aug-02-18	Reiterated	Maxim Group	Buy
Jul-13-18	Initiated	Stifel	Buy
Jul-12-18	Initiated	Cantor Fitzgerald	Overweight
Jun-12-18	Reiterated	H.C. Wainwright	Buy
Mar-15-18	Upgrade	Maxim Group	Hold → Buy
Feb-14-18	Downgrade	Maxim Group	Buy → Hold
Feb-12-18	Reiterated	H.C. Wainwright	Buy
Nov-15-17	Initiated	ROTH Capital	Buy
Aug-08-17	Reiterated	H.C. Wainwright	Buy
Jul-31-17	Reiterated	Maxim Group	Buy
Aug-01-16	Reiterated	Maxim Group	Buy
Jul-06-16	Resumed	ROTH Capital	Buy
Mar-28-16	Resumed	H.C. Wainwright	Buy
Jun-23-15	Initiated	H.C. Wainwright	Buy
May-06-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News

Apr 14, 2026

Galmed Pharmaceuticals Ltd. and Ramot At Tel Aviv University Enter Research Collaboration Agreement - marketscreener.com

Apr 14, 2026

Galmed partners with Tel Aviv University on brain cancer therapy By Investing.com - Investing.com Australia

Apr 14, 2026

Galmed Pharmaceuticals Teams with Tel Aviv University on Aramchol for Metastatic Brain Cancer - TipRanks

Apr 14, 2026

Galmed (NASDAQ: GLMD) and Tel Aviv University test Aramchol for brain cancer - Stock Titan

Apr 14, 2026

Apr 11, 2026

Galmed Stock Soars On Brain-Penetrating Aramchol FormulationGalmed Pharmaceuticals (NASDAQ:GLMD) - Benzinga

Apr 09, 2026

Galmed Unveils Brain-Penetrant Aramchol Formulation, Expanding Flagship Drug Into CNS Diseases - TipRanks

Apr 09, 2026

Galmed Pharmaceuticals Maps Future with Aramchol Strategy - timothysykes.com

Apr 09, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Apr 09, 2026

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol - ChartMill

Apr 09, 2026

Apr 02, 2026

[EFFECT] Galmed Pharmaceuticals Ltd. SEC Filing - Stock Titan

Apr 02, 2026

Mar 31, 2026

Going concern doubts and funding limits in Galmed (NASDAQ: GLMD) 2025 20-F - Stock Titan

Mar 31, 2026

MEDIA ADVISORY – Minister LeBlanc, Secretary of State Long and Parliamentary Secretary Myles to highlight investments supporting the Canadian Armed Forces following achievement of the NATO 2% defence spending target - Weekly Voice

Mar 31, 2026

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - ChartMill

Mar 31, 2026

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 31, 2026

Ideas Watch: Is Galmed Pharmaceuticals Ltd stock a good dividend stock2026 Update & Entry and Exit Point Strategies - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Portfolio Update: Can Galmed Pharmaceuticals Ltd grow without dilution2026 Recap & Safe Entry Point Alerts - baoquankhu1.vn

Mar 30, 2026

Mar 25, 2026

GLMD Stock Price, Quote & Chart | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill

Mar 25, 2026

Mar 18, 2026

Sectors Review: Can Galmed Pharmaceuticals Ltd deliver consistent dividendsMarket Rally & Low Risk Growth Stock Ideas - baoquankhu1.vn

Mar 18, 2026

Galmed (GLMD) director David Sidransky reports initial share and option holdings - Stock Titan

Mar 18, 2026

Galmed (GLMD) CFO details Ordinary Share, option and RSU holdings - Stock Titan

Mar 18, 2026

[Form 3] Galmed Pharmaceuticals Ltd. In... - Stock Titan

Mar 18, 2026

Galmed Pharmaceuticals (NASDAQ: GLMD) CAO reports shares, options and RSUs - stocktitan.net

Mar 18, 2026